VWA
CRSP icon

VSM Wealth Advisory’s CRISPR Therapeutics CRSP Stock Holding History

VSM Wealth Advisory’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.45K Hold
100
– – ﹤0.01% 408
2026
Q1 		$4.76K Buy
+100
New +$5.27K ﹤0.01% 412
2025
Q4 		– Sell
-100
Closed -$6.48K – 455
2025
Q3 		$6.48K Hold
100
– – ﹤0.01% 364
2025
Q2 		$4.86K Hold
100
– – ﹤0.01% 432
2025
Q1 		$3.4K Buy
+100
New +$4.24K ﹤0.01% 435

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VSM Wealth Advisory's CRSP Position: Q2 2026 in Review

VSM Wealth Advisory held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 100 shares worth $5.45K. The position accounts for ﹤0.01% of the portfolio, ranked #408.

VSM Wealth Advisory first reported a position in CRSP in Q1 2025 and has held it in 5 quarters since. The position peaked at $6.48K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • VSM Wealth Advisory held 100 shares of CRISPR Therapeutics worth $5.45K as of Q2 2026.
  • VSM Wealth Advisory left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of VSM Wealth Advisory's portfolio in Q2 2026, its #408 holding.
  • VSM Wealth Advisory first reported a position in CRISPR Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • VSM Wealth Advisory's CRISPR Therapeutics position peaked at $6.48K in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on VSM Wealth Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.